Emergent BioSolutions (NYSE:EBS - Get Free Report) released its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, beating analysts' consensus estimates of ($0.33) by $0.14, Yahoo Finance reports. Emergent BioSolutions had a negative return on equity of 28.54% and a negative net margin of 72.06%. During the same quarter last year, the firm earned ($0.31) earnings per share.
Emergent BioSolutions Stock Performance
EBS opened at $3.41 on Wednesday. Emergent BioSolutions has a 12-month low of $1.42 and a 12-month high of $13.67. The stock has a fifty day simple moving average of $2.15 and a two-hundred day simple moving average of $2.65. The company has a current ratio of 1.09, a quick ratio of 0.55 and a debt-to-equity ratio of 0.64.
Institutional Investors Weigh In On Emergent BioSolutions
A number of institutional investors have recently modified their holdings of EBS. State Street Corp grew its stake in shares of Emergent BioSolutions by 25.7% in the second quarter. State Street Corp now owns 6,794,144 shares of the biopharmaceutical company's stock worth $49,937,000 after acquiring an additional 1,388,594 shares during the last quarter. BlackRock Inc. boosted its position in shares of Emergent BioSolutions by 8.1% during the first quarter. BlackRock Inc. now owns 8,731,904 shares of the biopharmaceutical company's stock valued at $358,533,000 after buying an additional 655,003 shares during the last quarter. Balyasny Asset Management LLC purchased a new stake in shares of Emergent BioSolutions during the third quarter valued at $11,478,000. Norges Bank purchased a new stake in shares of Emergent BioSolutions during the fourth quarter valued at $5,016,000. Finally, Renaissance Technologies LLC purchased a new stake in shares of Emergent BioSolutions during the first quarter valued at $14,699,000. 88.26% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
A number of analysts have recently weighed in on the company. StockNews.com raised Emergent BioSolutions from a "sell" rating to a "hold" rating in a research note on Tuesday, December 12th. JPMorgan Chase & Co. restated an "underweight" rating on shares of Emergent BioSolutions in a report on Monday, November 20th.
Check Out Our Latest Stock Report on Emergent BioSolutions
About Emergent BioSolutions
(
Get Free Report)
Emergent BioSolutions Inc, a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. Its products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; public health crises; and acute, emergency, and community care.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Emergent BioSolutions, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Emergent BioSolutions wasn't on the list.
While Emergent BioSolutions currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
